Correlation Between Inozyme Pharma and Monopar Therapeutics
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Monopar Therapeutics, you can compare the effects of market volatilities on Inozyme Pharma and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Monopar Therapeutics.
Diversification Opportunities for Inozyme Pharma and Monopar Therapeutics
-0.78 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Inozyme and Monopar is -0.78. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Monopar Therapeutics go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Monopar Therapeutics
Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Monopar Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Inozyme Pharma is 38.31 times less risky than Monopar Therapeutics. The stock trades about -0.75 of its potential returns per unit of risk. The Monopar Therapeutics is currently generating about 0.2 of returns per unit of risk over similar time horizon. If you would invest 463.00 in Monopar Therapeutics on August 24, 2024 and sell it today you would earn a total of 1,508 from holding Monopar Therapeutics or generate 325.7% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inozyme Pharma vs. Monopar Therapeutics
Performance |
| Timeline |
| Inozyme Pharma |
| Monopar Therapeutics |
Inozyme Pharma and Monopar Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inozyme Pharma and Monopar Therapeutics
The main advantage of trading using opposite Inozyme Pharma and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.| Inozyme Pharma vs. Lyra Therapeutics | Inozyme Pharma vs. Hookipa Pharma | Inozyme Pharma vs. Cingulate Warrants | Inozyme Pharma vs. SAB Biotherapeutics |
| Monopar Therapeutics vs. Lyra Therapeutics | Monopar Therapeutics vs. Hookipa Pharma | Monopar Therapeutics vs. Cingulate Warrants | Monopar Therapeutics vs. SAB Biotherapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Complementary Tools
| Transaction History View history of all your transactions and understand their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |